{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T09:11:36Z","timestamp":1764407496920,"version":"3.46.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clinthera.2025.09.015","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T11:30:10Z","timestamp":1760009410000},"page":"1155-1160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Upper Respiratory Tract Infection Associated with Anti-HER2 Antibody Blockade for HER2-Positive Breast Cancer: A Bayesian Disproportionality Analysis Using Data From the FDA Adverse Event Reporting System"],"prefix":"10.1016","volume":"47","author":[{"given":"Jie","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clinthera.2025.09.015_bib0001","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127404","article-title":"Efficacy and safety of HER2-targeted agents for breast cancer with HER2-overexpression: a network meta-analysis","volume":"10","author":"Yu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2025.09.015_bib0002","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/415170","article-title":"Mechanisms of resistance to trastuzumab and novel therapeutic strategies in HER2-positive breast cancer","volume":"2012","author":"Wong","year":"2012","journal-title":"Int J Breast Cancer"},{"issue":"1","key":"10.1016\/j.clinthera.2025.09.015_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexmp.2009.05.001","article-title":"The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies","volume":"87","author":"Freudenberg","year":"2009","journal-title":"Exp Mol Pathol"},{"issue":"21","key":"10.1016\/j.clinthera.2025.09.015_bib0004","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1158\/1078-0432.CCR-14-1268","article-title":"First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer","volume":"20","author":"Amiri-Kordestani","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.clinthera.2025.09.015_bib0005","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1158\/1078-0432.CCR-13-0518","article-title":"Pertuzumab: optimizing HER2 blockade","volume":"19","author":"Metzger-Filho","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clinthera.2025.09.015_bib0006","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.clinthera.2025.09.015_bib0007","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13058-021-01459-y","article-title":"Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions","volume":"23","author":"Ferraro","year":"2021","journal-title":"Breast Cancer Res"},{"issue":"17","key":"10.1016\/j.clinthera.2025.09.015_bib0008","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1158\/1078-0432.CCR-14-0012","article-title":"FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer","volume":"20","author":"Amiri-Kordestani","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clinthera.2025.09.015_bib0009","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clinthera.2025.09.015_bib0010","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clinthera.2025.09.015_bib0011","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10549-014-3190-5","article-title":"Skin\/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy","volume":"148","author":"Mortimer","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.clinthera.2025.09.015_bib0012","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1186\/s12885-023-11250-1","article-title":"Incidence and risk of fatal adverse events in cancer patients treated with HER2-targeted antibody-drug conjugates: a systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Fu","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.clinthera.2025.09.015_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-021-06469-0","article-title":"Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review","volume":"194","author":"Perez","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clinthera.2025.09.015_bib0014","unstructured":"European Medicines Agency. (2024). Enhertu (trastuzumab deruxtecan) risk management plan. Retrieved from https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/enhertu-epar-risk-management-plan_en.pdf."},{"issue":"5","key":"10.1016\/j.clinthera.2025.09.015_bib0015","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.clgc.2023.07.003","article-title":"Cardiovascular adverse events associated with new-generation androgen receptor pathway inhibitors (ARPI) for prostate cancer: a disproportionality analysis based on the FDA adverse event reporting system (FAERS)","volume":"21","author":"Liu","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clinthera.2025.09.015_bib0016","first-page":"689","article-title":"Guideline for rational medication of acute upper respiratory tract infection in primary care","volume":"19","year":"2020","journal-title":"Chin J Gen Pract"},{"key":"10.1016\/j.clinthera.2025.09.015_bib0017","first-page":"1","article-title":"Cardiovascular adverse events associated with PARP inhibitors for ovarian cancer: a real-world study (RWS) with Bayesian disproportional analysis based on the FDA adverse event reporting system (FAERS)","author":"Yang","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"10.1016\/j.clinthera.2025.09.015_bib0018","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","article-title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","volume":"18","author":"Di\u00e9ras","year":"2017","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.clinthera.2025.09.015_bib0019","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clinthera.2025.09.015_bib0020","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/21505594.2016.1141161","article-title":"Bloodstream infections in patients with solid tumors","volume":"7","author":"Gudiol","year":"2016","journal-title":"Virulence"},{"issue":"8","key":"10.1016\/j.clinthera.2025.09.015_bib0021","first-page":"2391","article-title":"Nasal vestibulitis due to targeted therapies in cancer patients","volume":"23","author":"Ruiz","year":"2015","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.clinthera.2025.09.015_bib0022","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1600-065X.2010.00987.x","article-title":"Infection, immunoregulation, and cancer","volume":"240","author":"Rook","year":"2011","journal-title":"Immunol Rev"},{"issue":"5","key":"10.1016\/j.clinthera.2025.09.015_bib0023","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1208\/s12248-015-9790-0","article-title":"Antibody drug conjugates: nonclinical safety considerations","volume":"17","author":"Hinrichs","year":"2015","journal-title":"AAPS J"},{"key":"10.1016\/j.clinthera.2025.09.015_bib0024","article-title":"Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations","volume":"62","author":"D'Arienzo","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"6","key":"10.1016\/j.clinthera.2025.09.015_bib0025","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1159\/000480492","article-title":"Adverse Events of Trastuzumab Emtansine (T-DM1) in the Treatment of HER2-Positive Breast Cancer Patients","volume":"12","author":"Kowalczyk","year":"2017","journal-title":"Breast Care (Basel)"},{"issue":"5","key":"10.1016\/j.clinthera.2025.09.015_bib0026","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00280-011-1817-3","article-title":"Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer","volume":"69","author":"Girish","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"10.1016\/j.clinthera.2025.09.015_bib0027","doi-asserted-by":"crossref","first-page":"7968","DOI":"10.1073\/pnas.092697199","article-title":"The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnema pretiosum","volume":"99","author":"Yu","year":"2002","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"25","key":"10.1016\/j.clinthera.2025.09.015_bib0028","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1200\/JCO.2013.54.4999","article-title":"Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis","volume":"32","author":"Di\u00e9ras","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clinthera.2025.09.015_bib0029","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1177\/0192623318803059","article-title":"A Brief Introduction to Antibody-Drug Conjugates for Toxicologic Pathologists","volume":"46","author":"Mecklenburg","year":"2018","journal-title":"Toxicol Pathol"},{"issue":"24_Supplement","key":"10.1016\/j.clinthera.2025.09.015_bib0030","doi-asserted-by":"crossref","first-page":"P3-14-22","DOI":"10.1158\/0008-5472.SABCS10-P3-14-22","article-title":"Abstract P3-14-22: Pharmacokinetics (PK) of Trastuzumab-DM1 (T-DM1) and Paclitaxel (T) in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer (MBC) Previously Treated with a Trastuzumab-Containing Regimen","volume":"70","author":"Lu","year":"2010","journal-title":"Cancer Res"},{"issue":"Suppl 10","key":"10.1016\/j.clinthera.2025.09.015_bib0031","first-page":"S11","article-title":"Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future","volume":"57","author":"Vezina","year":"2017","journal-title":"J Clin Pharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182500325X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182500325X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T09:09:57Z","timestamp":1764407397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929182500325X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S014929182500325X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.09.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Upper Respiratory Tract Infection Associated with Anti-HER2 Antibody Blockade for HER2-Positive Breast Cancer: A Bayesian Disproportionality Analysis Using Data From the FDA Adverse Event Reporting System","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}